Imunon has confirmed the deprioritization of its COVID-19 vaccine program. With the company’s cash reserves falling below $5 ...

Imunon, Inc. ( NASDAQ: IMNN) Q2 2025 Earnings Conference Call August 5, 2025 11:00 AM ET Douglas V. Faller - Chief Medical Officer Khursheed Anwer - Executive VP & Chief Scientific Officer Kimberly ...

Stock dividend issued to IMUNON shareholders reflects confidence in clinical programs, long-term growth strategy and dedication to rewarding shareholders First patient dosed in Phase 3 OVATION 3 Study ...

Imunon, Inc. (($IMNN)) announced an update on their ongoing clinical study. Imunon, Inc. is conducting a Phase 3 clinical trial titled A ...

Analysts expect Imunon to report an earnings per share (EPS) of $-3.09. The market awaits Imunon's announcement, with hopes high for news of surpassing estimates and providing upbeat guidance for the ...

The current quarter introduced the 15% onetime stock dividend and confirmed accelerated site activation for OVATION 3, compared to the previous quarter's focus on initial site readiness and ...

Investors are reminded that Shareholders of record as of August 7, 2025, will receive a 15% stock dividend payment LAWRENCEVILLE, N.J., Aug. 05, 2025 (GLOBE NEWSWIRE) -- IMUNON, Inc. (Nasdaq: IMNN), a ...

Furthermore, IMUNON’s Phase 2 OVATION 2 Study of IMNN-001 for ovarian cancer showed significant improvements in survival rates, indicating promise for future treatment options.

Initiation of additional trial sites and patient enrollment activities ongoing with multiple patients in screening LAWRENCEVILLE, N.J., July 30, 2025 (GLOBE NEWSWIRE) -- IMUNON, Inc. (Nasdaq: IMNN), ...

(Nasdaq: IMNN), a clinical-stage company in Phase 3 development of its DNA-mediated immunotherapy, today announced that the first patient has been dosed in the pivotal Phase 3 OVATION 3 Study ...

Additionally, Imunon is facing potential delisting from the Nasdaq Capital Market due to non-compliance with minimum bid price and stockholders’ equity requirements.

IMUNON announces promising Phase 1 results for IMNN-101, a DNA plasmid vaccine demonstrating enhanced durability and potential advantages over mRNA vaccines.